Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept

Maria Cristina Maggio, Luciana Breda, Alessandro Consolaro, Romina Gallizzi, Sergio Davì, Valentina Muratore, Francesco Zulian, Nicolino Ruperto, Rebecca Nicolai, Francesco La Torre, Serena Pastore, Sara Verazza, Alma Nunzia Olivieri, Adele Civino, Achille Marino, Denise Pires Marafon, Chiara Sandrin, Francesca Bovis, Donato Rigante, Denise Pires MarafonAlessandro De Fanti, Francesca Rovelli, Claudia Fede, Rosanna Podda, Alessandro De Fanti, Irene Pontikaki, Rosanna Podda, Antonella Insalaco, Elisabetta Cortis, Mauro Jorini, Marta Torcoletti, Maria Giannina Alpigiani, Silvia Magni-Manzoni, Alessandro De Fanti, Marco Cattalini, Rita Consolini, Valeria Gerloni, Fabrizia Corona, Rolando Cimaz, Maria Cristina Maggio, Fabrizio De Benedetti, Angelo Ravelli, Giorgia Martini, Patrizia Barone, Gianfranco D'Angelo, Alberto Martini, Giovanni Conti

Risultato della ricerca: Articlepeer review

22 Citazioni (Scopus)

Abstract

Background: Data from routine clinical practice are needed to further define the efficacy and safety of biologic medications in children with juvenile idiopathic arthritis (JIA). The aim of this analysis was to investigate the disease status, reasons for discontinuation and adverse events in Italian JIA patients treated with etanercept (ETN). Methods: In 2013, all centers of the Italian Pediatric Rheumatology Study Group were asked to make a census of patients given ETN after January 2000. Patients were classified in three groups: group 1 = patients still taking ETN; group 2 = patients discontinued from ETN for any reasons; group 3 = patients lost to follow-up while receiving ETN. All three groups received a retrospective assessment; patients in group 1 also underwent a cross-sectional assessment. Results: 1038 patients were enrolled by 23 centers: 422 (40.7%) were in group 1, 462 (44.5%) in group 2, and 154 (14.8%) in group 3. Median duration of ETN therapy was 2.5 years. At cross-sectional assessment, 41.8% to 48.6% of patients in group 1 met formal criteria for inactive disease, whereas 52.4% of patients in group 2 and 55.8% of patients in group 3 were judged in clinical remission by their caring physician at last visit. A relatively greater proportion of patients with systemic arthritis were discontinued or lost to follow-up. Parent evaluations at cross-sectional visit in group 1 showed that 52.4% of patients had normal physical function, very few had impairment in quality of life, 51.2% had no pain, 76% had no morning stiffness, and 82.7% of parents were satisfied with their child's illness outcome. Clinically significant adverse events were reported for 27.8% of patients and ETN was discontinued for side effects in 9.5%. The most common adverse events were new onset or recurrent uveitis (10.2%), infections (6.6%), injection site reactions (4.4%), and neuropsychiatric (3.1%), gastrointestinal (2.4%), and hematological disorders (2.1%). Ten patients developed an inflammatory bowel disease and 2 had a malignancy. One patient died of a fulminant streptococcal sepsis. Conclusions: Around half of the patients achieved complete disease quiescence under treatment with ETN. The medication was overall well tolerated, as only one quarter of patients experienced clinically significant adverse events and less than 10% had treatment discontinued for toxicity.
Lingua originaleEnglish
pagine (da-a)68-78
Numero di pagine11
RivistaPEDIATRIC RHEUMATOLOGY ONLINE JOURNAL
Volume14
Stato di pubblicazionePublished - 2016

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Rheumatology
  • Immunology and Allergy

Fingerprint Entra nei temi di ricerca di 'Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept'. Insieme formano una fingerprint unica.

Cita questo